Biography

Dillon Li, M.D., Assistant Professor, is a radiation oncologist at UT Southwestern Medical Center focused on treating breast cancer.

After graduating from Peking University Health Science Center summa cum laude, Dr. Li received his M.P.H. from the University of Cincinnati College of Medicine and his medical degree from the University of Kentucky College of Medicine. He completed his radiation oncology residency at Memorial Sloan Kettering Cancer Center, which provides one of the most robust training programs in the world for lymphoma and pediatric radiation oncology. During his residency, his research focused on the genomic basis of radiosensitivity and advanced radiotherapy delivery technologies, and he has a keen interest and passion in furthering our precision and personalized radiation oncology program. In fact, as a radiation oncology resident, he was awarded an ASCO Young Investigator Award to this end.

Education

Medical School
University of Kentucky College of Medicine (2017)
Internship
Santa Clara Valley Medical Center (2018), Transitional Year
Residency
Memorial Sloan Kettering Cancer Center (2022), Radiation Oncology

Publications

Featured Publications LegendFeatured Publications

Local Consolidative Therapy for Oligometastatic Non-Small Cell Lung Cancer.
Santos PMG, Li X, Gomez DR, Cancers (Basel) 2022 Aug 14 16
A narrative review of intensity-modulated proton therapy for head and neck cance
Nader Mohamed, Xingzhe Li, Nancy Y. Lee Ther Radiol Oncol 2022
The inflammatory response from stereotactic body proton therapy versus stereotactic body radiation therapy: implications from early stage non-small cell lung cancer.
Li XD, Simone CB, Ann Transl Med 2019 Dec 7 Suppl 8 S295
Comparison of outcomes of stereotactic body radiation therapy delivered with three different technologies to the lung.
Kumar SS, Hall L, Li X, Downes L, Shearer A, Shelton BJ, Gerring S, McGarry RC, J Radiosurg SBRT 2018 5 3 209-216
Update of a Prospective Study of Stereotactic Body Radiation Therapy for Post-Chemoradiation Residual Disease in Stage II/III Non-Small Cell Lung Cancer.
Kumar S, Feddock J, Li X, Shearer AJ, Hall L, Shelton BJ, Arnold S, McGarry RC Int. J. Radiat. Oncol. Biol. Phys. 2017 Nov 99 3 652-659